David Brian Perez

Board Director

Director

Ortho Clinical Diagnostics Holdings plcNeogenomics Inc

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 1 buy · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€67k

▼ Sales (0 ops.)

—

Latest filing published 03 Jun 2025 for Neogenomics INC.

Filing timeline

BuySale

David Brian Perez

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

100%

T+90 mean return

+20.6%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

David Brian Perez: trading record in brief

Filings by David Brian Perez span 3 companies, the busiest being Neogenomics Inc, Ortho Clinical Diagnostics Holdings plc and Mesa Laboratories Inc /CO/. Between 7 November 2019 and 1 June 2025, the trades on record add up to 7 filings.

Purchases make up the whole of the open-market record (1 purchase, €67k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 2 share grants and 3 option exercises. Since January 2025: 1 purchase and no sales on the market.

The latest filing, published on 3 June 2025, reports an option exercise in Neogenomics Inc. The clock since the last published purchase (7 May 2025) now reads 535 days. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.